SEC Comment Letter 0000000000-26-003549 to 20/20 Biolabs, Inc. (AIDX)
20/20 Biolabs, Inc.
Date: April 8, 2026 · CIK: 0001139685 · Accession: 0000000000-26-003549
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294903
Letter
Re: 20/20 Biolabs, Inc. Registration Statement on Form S-1 Filed April 6, 2026 File No. 333-294903 Dear Jonathan Cohen:
April 8, 2026
Jonathan Cohen Chief Executive Officer 20/20 Biolabs, Inc. 15810 Gaither Road Suite 235 Gaithersburg, MD 20877
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Robert Augustin at 202-551-8483 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Industrial
Applications and Services
cc: Louis A. Bevilacqua, Esq.
Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
April 8, 2026
Jonathan Cohen
Chief Executive Officer
20/20 Biolabs, Inc.
15810 Gaither Road
Suite 235
Gaithersburg, MD 20877
Re: 20/20 Biolabs, Inc.
Registration Statement on Form S-1
Filed April 6, 2026
File No. 333-294903
Dear Jonathan Cohen:
This is to advise you that we have not reviewed and will not review your
registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.
Please contact Robert Augustin at 202-551-8483 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Industrial
Applications and Services
cc: Louis A. Bevilacqua, Esq.
</TEXT>
</DOCUMENT>